OVID
Ovid Therapeutics Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
2.80
▲ 0.06 (2.19%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
2.80
Prev close
2.74
Day high
2.83
Day low
2.71
Volume
1.33M
Market cap
—
P/E (TTM)
—
52W range
1.05 – 3.11
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-1.06%
+0.3%
1M
+16.67%
+12.9%
3M
+14.75%
+11.7%
6M
+90.48%
+79.4%
YTD
+71.78%
+59.5%
1Y
+194.74%
+174.7%
3Y
-25.93%
-100.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $7.25M | $566.00K | $392.00K | $1.50M | +1,181.3% |
| Operating revenue | $7.25M | $566.00K | $392.00K | $1.50M | +1,181.3% |
| Research & development | $25.58M | $36.77M | $28.59M | $24.62M | -30.4% |
| Selling, general & admin | $24.11M | $25.68M | $31.09M | $32.43M | -6.1% |
| Total operating expense | $49.69M | $62.45M | $59.67M | $57.05M | -20.4% |
| Operating income | -$42.44M | -$61.88M | -$59.28M | -$55.55M | +31.4% |
| Net interest income | — | $3.90M | $4.90M | — | — |
| Pre-tax income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | +34.1% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | +34.1% |
| Net income to common | -$17.41M | -$26.43M | -$52.34M | -$54.17M | +34.1% |
| Basic EPS | -0.23 | -0.37 | -0.73 | -0.77 | +37.8% |
| Diluted EPS | -0.23 | -0.37 | -0.73 | -0.77 | +37.8% |
| EBIT | -$42.44M | -$61.88M | -$59.28M | -$55.55M | +31.4% |
| EBITDA | -$42.17M | -$61.27M | -$58.71M | -$54.17M | +31.2% |
| Basic shares | 73.74M | 70.91M | 70.58M | 70.42M | +4.0% |
| Diluted shares | 73.74M | 70.91M | 70.58M | 70.42M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.15M | $26.30M | $27.04M | $44.87M | — | -50.0% |
| Cash & short-term investments | $69.64M | $53.08M | $105.83M | $129.00M | — | +31.2% |
| Total current assets | $74.37M | $55.94M | $109.60M | $131.38M | — | +32.9% |
| Property, plant & equipment | $11.86M | $13.23M | $14.66M | $16.07M | — | -10.3% |
| Goodwill & intangibles | — | — | $182.97K | $222.10K | $164.09K | — |
| Total assets | $150.93M | $92.17M | $144.03M | $155.27M | — | +63.8% |
| Total current liabilities | $8.29M | $10.52M | $11.47M | $6.99M | — | -21.2% |
| Total debt | $13.42M | $14.76M | $16.00M | $16.54M | — | -9.1% |
| Total liabilities | $20.27M | $23.94M | $56.23M | $22.99M | — | -15.3% |
| Retained earnings | -$321.71M | -$304.30M | -$277.87M | -$225.53M | — | -5.7% |
| Shareholder equity | $130.66M | $68.23M | $87.80M | $132.27M | — | +91.5% |
| Working capital | $66.08M | $45.42M | $98.13M | $124.39M | — | +45.5% |
| Net tangible assets | $130.66M | $68.23M | $87.80M | $132.05M | — | +91.5% |
| Shares issued | 130.18M | 71.01M | 70.69M | 70.47M | — | +83.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.41M | -$26.43M | -$52.34M | -$54.17M | — | +34.1% |
| Depreciation & amortisation | $273.00K | $613.00K | $568.00K | $1.38M | — | -55.5% |
| Stock-based compensation | $4.81M | $6.28M | $7.29M | $6.56M | — | -23.4% |
| Change in working capital | -$4.10M | -$150.00K | $2.39M | -$8.23M | — | -2,636.0% |
| Operating cash flow | -$38.33M | -$55.96M | -$45.78M | -$55.23M | — | +31.5% |
| Capital expenditure | — | -$161.00K | -$137.00K | -$1.42M | -$189.41K | — |
| Investing cash flow | -$49.85M | $54.59M | -$2.58M | -$87.88M | — | -191.3% |
| Financing cash flow | $75.21M | $622.00K | $30.54M | $180.66K | — | +11,991.2% |
| Free cash flow | -$38.33M | -$56.12M | -$45.92M | -$56.65M | — | +31.7% |
| End cash position | $15.08M | $28.23M | $28.97M | $46.80M | — | -46.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $718.00K | $132.00K | $6.27M | $130.00K | -100.0% |
| Operating revenue | $0 | $718.00K | $132.00K | $6.27M | $130.00K | -100.0% |
| Research & development | $11.18M | $6.59M | $5.87M | $6.46M | $6.66M | +69.7% |
| Selling, general & admin | $6.67M | $6.42M | $6.79M | $4.88M | $6.02M | +3.8% |
| Total operating expense | $17.85M | $13.01M | $12.65M | $11.35M | $12.68M | +37.2% |
| Operating income | -$17.85M | -$12.29M | -$12.52M | -$5.07M | -$12.55M | -45.2% |
| Pre-tax income | -$16.99M | $9.66M | -$12.16M | -$4.68M | -$10.23M | -275.8% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$16.99M | $9.66M | -$12.16M | -$4.68M | -$10.23M | -275.8% |
| Net income to common | -$16.99M | $9.66M | -$12.16M | -$4.68M | -$10.06M | -275.8% |
| Basic EPS | -0.12 | 0.06 | -0.17 | -0.06 | -0.14 | -300.0% |
| Diluted EPS | -0.12 | 0.06 | -0.17 | -0.06 | -0.14 | -300.0% |
| EBIT | -$17.85M | -$12.29M | -$12.52M | -$5.07M | -$12.55M | -45.2% |
| EBITDA | -$17.81M | -$12.28M | -$12.51M | -$4.97M | -$12.41M | -45.1% |
| Basic shares | 136.17M | 81.67M | 71.12M | 71.11M | 71.05M | +66.7% |
| Diluted shares | 136.17M | 81.67M | 71.12M | 71.11M | 71.05M | +66.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $94.06M | $13.15M | $20.61M | $28.41M | $21.14M | +615.2% |
| Cash & short-term investments | $155.52M | $69.64M | $25.60M | $38.35M | $43.00M | +123.3% |
| Total current assets | $160.15M | $74.37M | $28.82M | $42.09M | $45.92M | +115.3% |
| Property, plant & equipment | $11.52M | $11.86M | $12.19M | $12.50M | $12.86M | -2.9% |
| Total assets | $225.63M | $150.93M | $63.85M | $77.43M | $81.65M | +49.5% |
| Total current liabilities | $15.75M | $8.29M | $6.80M | $8.92M | $9.31M | +90.0% |
| Total debt | $13.07M | $13.42M | $13.76M | $14.10M | $14.43M | -2.6% |
| Total liabilities | $27.36M | $20.27M | $19.15M | $21.64M | $22.38M | +34.9% |
| Retained earnings | -$338.70M | -$321.71M | -$331.38M | -$319.22M | -$314.53M | -5.3% |
| Shareholder equity | $198.27M | $130.66M | $44.70M | $55.79M | $59.28M | +51.7% |
| Working capital | $144.40M | $66.08M | $22.03M | $33.16M | $36.61M | +118.5% |
| Net tangible assets | $198.27M | $130.66M | $44.70M | $55.79M | $59.28M | +51.7% |
| Shares issued | 167.27M | 130.18M | 71.15M | 71.11M | 71.11M | +28.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$16.99M | $9.66M | -$12.16M | -$4.68M | -$10.23M | -275.8% |
| Depreciation & amortisation | $35.00K | $17.00K | $16.00K | $99.00K | $141.00K | +105.9% |
| Stock-based compensation | $1.05M | $1.20M | $1.11M | $1.22M | $1.28M | -12.5% |
| Change in working capital | $2.33M | $134.00K | -$1.69M | -$1.24M | -$1.30M | +1,640.3% |
| Operating cash flow | -$13.90M | -$10.41M | -$12.87M | -$4.77M | -$10.28M | -33.5% |
| Investing cash flow | $5.95M | -$72.06M | $5.05M | $12.05M | $5.10M | +108.3% |
| Financing cash flow | $88.98M | $75.18M | $15.00K | $0 | $13.00K | +18.4% |
| Free cash flow | -$13.90M | -$10.41M | -$12.87M | -$4.77M | -$10.28M | -33.5% |
| End cash position | $96.00M | $15.08M | $22.54M | $30.35M | $23.07M | +536.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.76
+1.27% from price
SMA 20
2.60
+7.67% from price
SMA 50
2.52
+11.14% from price
SMA 100
2.57
+8.99% from price
SMA 200
2.12
+32.00% from price
EMA 12
2.74
+2.34% from price
EMA 26
2.63
+6.28% from price
EMA 50
2.57
+9.07% from price
RSI (14)
58.5
Neutral
MACD (12,26,9)
0.10
Hist 0.02
ATR (14)
0.15
5.34% of price
Realised vol 30D
55.7%
Annualised
Bollinger upper
3.02
20, 2σ
Bollinger lower
2.18
20, 2σ
50 / 200 cross
Golden
2.52 vs 2.12
Trend bias
Above 200
+32.00%
Risk profile
Beta vs SPY
1.28
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
55.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-34.8%
Peak to trough
Max drawdown 5Y
-93.7%
Peak to trough
ATR 14
0.15
5.34% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Zacks · 4d ago
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 9d ago
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
GlobeNewswire · 9d ago
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Zacks · 16d ago
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 16d ago
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Zacks · 17d ago
Oppenheimer Adjusts Ovid Therapeutics Price Target to $9 From $7, Maintains Outperform Rating
MT Newswires · 19d ago
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer
Insider Monkey · 40d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.